Abstracts tagged "Disease Activity"

Abstract Number: 3045 • 2015 ACR/ARHP Annual Meeting
Anti-Alpha-Enolase Antibodies in Behçet’s Disease: A Marker of Articular Disease Activity?
Leandro L. Prado, Celio R. Gonçalves, Vilma S. T. Viana, Eloisa Bonfá and Carla G.S. Saad, Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Diagnosis of Behçet´s disease (BD) is challenging because is based solely on clinical features. Articular involvement in this disease may mimic other diagnosis such…
Abstract Number: 169 • 2015 ACR/ARHP Annual Meeting
Ultrasonographic Signs of Inflammation of Metatarsophalangeal Joints in Rheumatoid Arthritis Patients Who Are Treated to Target
Myrthe van der Ven¹, David F. Ten Cate², Andreas Gerards³, Johannes Jacobs⁴, Nanno Swen⁵, M.H. de Jager⁶, Natalja Basoski⁷, Cees Haagsma⁸, Mieke Hazes¹ and J.J. Luime¹, ¹Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ²Department of Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ³Rheumatology, Vlietland Hospital, Schiedam, Netherlands, ⁴Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Rheumatology, Medical Center Alkmaar, Alkmaar, Netherlands, ⁶Department of Rheumatology, Albert Schweitzer Hospital, Dordrecht, Netherlands, ⁷Rheumatology, Maasstadziekenhuis, Rotterdam, Netherlands, ⁸Rheumatology, Ziekenhuisgroep Twente, Almelo, Netherlands
Background/Purpose: The feet are often involved in rheumatoid arthritis (RA), but physical examination of the metatarsophalangeal (MTP) joints to detect arthritis is challenging especially in…
Abstract Number: 533 • 2015 ACR/ARHP Annual Meeting
The Interferon Gene Signature in Early Rheumatoid Arthritis Demonstrates No Significant Association with Disease Activity
Faye A H Cooles¹, Amy E. Anderson², Catharien Hilkens³ and John D Isaacs⁴, ¹Musculoskeletal Research Group, Newcastle University, Newcastle upon Tyne, United Kingdom, ²Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, ³Musculoskeletal Research Group, Newcastle University, Newcastle Upon Tyne, United Kingdom, ⁴Newcastle University and the Freeman Hospital, Newcastle-upon-Tyne, United Kingdom
Background/Purpose: An interferon-α gene signature (IGS) has been demonstrated in a number of rheumatological conditions, including rheumatoid arthritis (RA) where it is present in about…
Abstract Number: 735 • 2015 ACR/ARHP Annual Meeting
Belimumab Reduces the Frequency of Flares and Prevents Damage Progression in SLE Patients: Experience in a Clinical Practice Setting
Luca Iaccarino¹, Silvano Bettio¹, Rossella Reggia², Margherita Zen³, Micol Frassi², Laura Andreoli², Linda Nalotto¹, Mariele Gatto¹, Lara Pea², Nicola Bassi¹, Maddalena Larosa¹, Alessandra Zanola², Leonardo Punzi⁴, Angela Tincani² and Andrea Doria¹, ¹Department of Medicine-DIMED, University of Padova, Padova, Italy, ²Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ³Division of Rheumatology, University of Padova, Padova, Italy, ⁴Unit of Rheumatology, University of Padova, Padova, Italy
Background/Purpose: To investigate the efficacy and safety of belimumab in patients affected with active systemic lupus erythematosus (SLE) refractory to standard therapy. Methods: Fifty-eight patients,…
Abstract Number: 1550 • 2015 ACR/ARHP Annual Meeting
Flares of Disease Activity As Risk Factor for the Occurrence of Myocardial Infarction in Patients with Rheumatoid Arthritis
Esmee Bakker¹, Pauline Geuijen², Beata Radovits¹, Delia Popa-Diaconu¹, Calin Popa¹, Elke Arts¹, Alfons A. den Broeder³ and Jaap Fransen¹, ¹Rheumatology, Radboud University Medical Centre, Nijmegen, Netherlands, ²Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ³Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) patients have an increased risk of cardiovascular diseases (CVD). The underlying mechanism is partly explained by the inflammation process in both…
Abstract Number: 2069 • 2015 ACR/ARHP Annual Meeting
High Interferon Gene Signature Is Associated with Increased Disease Activity, Reduced Complement C3 and C4, and Increased Oral Corticosteroid Use in Systemic Lupus Erythematosus (SLE)
K Ranade, L Wang, P Brohawn, W Greth, J Drappa and G Illei, MedImmune, Gaithersburg, MD
Background/Purpose: Increased expression of genes inducible by type 1 interferons has been observed in a subset of patients with systemic lupus erythematosus (SLE). Oral corticosteroids…
Abstract Number: 2532 • 2015 ACR/ARHP Annual Meeting
Disease Activity in Women with Systemic Lupus Erythematosus during Pregnancy and the First Year Post Partum
Carina Gotestam Skorpen^1,2, Johan Skomsvoll³, Inge-Margrethe Gilboe⁴, Stian Lydersen⁵ and Marianne Wallenius³, ¹Dept of Neuroscience, Norwegian University of Science and Technology (NTNU), Trondheim, Norway, ²Dept of Rheumatology, Trondheim University Hospital, Norwegian National Advisory Unit on Pregnancy and Rheumatic Diseases, Trondheim, Norway, ³Dept of Rheumatology, Trondheim University Hospital, National Advisory Unit on Pregnancy and Rheumatic Diseases, Trondheim, Norway, ⁴Revmatologisk avdeling seksjon, Oslo universitetssykehus HF, Rikshospitalet, Oslo, Norway, ⁵Regional Center for the health of children and adolescents, Norwegian University of Science and Technology (NTNU), Trondheim, Norway
Disease Activity in women with SLE during pregnancy and the first year post partumBackground/Purpose: Disease activity measured by validated methods has been sparsely examined during…
Abstract Number: 2672 • 2015 ACR/ARHP Annual Meeting
Determinants of Patient- Physician Discordance in Assessment of Global Disease Activity in Latinos with Rheumatoid Arthritis in the United States
George A. Karpouzas¹, Taylor Draper², Elizabeth Hernandez¹ and Sarah Ormseth¹, ¹Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ²Psychology, Loma Linda University, Loma Linda, CA
Background/Purpose: Patients and physicians often differ in their perceptions of disease activity in Rheumatoid arthritis (RA) as described by patients' and evaluators' global assessments (PGA…
Abstract Number: 3058 • 2015 ACR/ARHP Annual Meeting
NMR-Based Metabolomics Provides New Insights into the Inflammatory Processes in Takayasu Arteritis
Ramnath Misra¹, Anupam Guleria², Durga Prasanna Misra¹, Avadesh Pratap³, Durgesh Dubey⁴, Atul Rawat⁴, Smriti Chaurasia³, C L Khetrapal⁴, Dinesh Kumar⁴ and Paul Bacon⁵, ¹Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Centre of Biomedical Research, Lucknow, India, ³S.G.P.G.I.M.S, Department of Clinical Immunology, Lucknow, India, ⁴Centre for Biomedical Research, Lucknow, India, ⁵Rheumatology, Birmingham Universit, Birmingham, United Kingdom
Background/Purpose: Takayasu Arteritis (TA), a large vessel disease of unknown aetiology, is the orphan of the inflammatory vasculitides with no evidence base for therapy. It…
Abstract Number: 2 • 2015 ACR/ARHP Annual Meeting
The Neutrophil Protein S100A12 Has Stronger Associations with a Comprehensive Ultrasound Score of Synovitis Than Vascular Endothelial Growth Factor in a Longitudinal Study of Rheumatoid Arthritis Patients
Hilde Haugedal Nordal^1,2 and Hilde Berner Hammer³, ¹Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway, ²Department of Rheumatology, Haukeland University Hospital, Bergen, Norway, ³Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: S100A12, a neutrophil protein, has proinflammatory effects on immune cells and can activate endothelial cells. The mechanism of action suggests vascular endothelial growth factor…
Abstract Number: 171 • 2015 ACR/ARHP Annual Meeting
Serum Calprotectin Levels Correlate with Ultrasonographic Synovitis in Rheumatoid Arthritis Patients
Jana Hurnakova¹, Jakub Zavada¹, Petra Hanova¹, Hana Hulejová¹, Martin Klein¹, Herman F Mann¹, Olga Sleglova¹, Marta Olejarova¹, Šárka Forejtová¹, Olga Ruzickova¹, Martin Komarc², Jiri Vencovsky¹, Karel Pavelka¹ and Ladislav Senolt¹, ¹Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ²Institute of Biophysics and Informatics of the First Faculty of Medicine, Charles University, Prague, Czech Republic
Background/Purpose: Calprotectin (S100A8/9, MRP8/14) has been demonstrated as a promising biomarker of clinical and laboratory disease activity in rheumatoid arthritis (RA). In addition, two small…
Abstract Number: 535 • 2015 ACR/ARHP Annual Meeting
Taurine As a Biomarker for Prediction of Response to Biologic Therapy in Rheumatoid Arthritis
Soshi Takahashi¹, Jun Saegusa², Ikuko Naka¹, Kosaku Tsuda¹, Takaichi Okano¹, Kengo Akashi¹, Miwa Nishida¹, Keisuke Nishimura², Sho Sendo², Yo Ueda¹, Akira Onishi³, Yoshinori Kogata², Goichi Kageyama² and Akio Morinobu², ¹Department of Rheumatology, Kobe University Hospital, Kobe, Japan, ²Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ³Rheumaology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan
Background/Purpose: To identify a serum biomarker for prediction of the response to biologics (Bio) in patients with rheumatoid arthritis (RA), we performed serum metabolomics analysis…
Abstract Number: 757 • 2015 ACR/ARHP Annual Meeting
The Ratio Between TNF-a and P-Albumin – a Suggested Measure of Disease Activity in SLE
Susanna Eketjäll¹, Helena Idborg², Johanna Gustafsson³, Agneta Zickert², Marika Kvarnstrom⁴, Vilija Oke⁵, Susanne Pettersson⁴, Per Johan Jakobsson⁴, Iva Gunnarsson⁴ and Elisabet Svenungsson⁴, ¹Department of Clinical Neuroscience, Karolinska Institutet, Solna, AstraZeneca Translational Sciences Centre, Science for Life Laboratory, Personal Healthcare and Biomarkers, Stockholm, Sweden, ²Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ³Department of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁴Department of Medicine, Unit of Rheumatology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁵Department of medicine, Unit of Rheumatology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: There is presently no consensus on how to best measure disease activity in systemic lupus erythematosus (SLE). Available validated measures, such as SLE Disease…
Abstract Number: 1560 • 2015 ACR/ARHP Annual Meeting
The Effect of Anti Estrogen Therapy (AET) on Rheumatoid Arthritis
Bassam Alhaddad¹, Amrita Kaur Bath², Bassem Zraik³, Mohamed Alalwani⁴ and Stanley P Ballou¹, ¹Rheumatology, Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH, ²Internal medicine, Fairview Hospital- Cleveland Cinic, Cleveland, OH, ³Internal Medicine, Fairview Hospital- Cleveland Clinic, cleveland, OH, ⁴Hospital Medicine, Cleveland Clinic, Cleveland, OH
Background/Purpose: The well-known positive effect of pregnancy on improving Rheumatoid Arthritis (RA) disease activity suggests that hormonal changes may play a role in disease pathogenesis…
Abstract Number: 2277 • 2015 ACR/ARHP Annual Meeting
Working Harder to Stay in Control: Patient Reports of Flare in Early RA Are Associated with Higher Disease Activity and More Intensive Self Management
Susan J. Bartlett^1,2, Clifton O. Bingham III³, Daming Lin⁴, Kathleen Andersen⁵, Gilles Boire⁶, Carol Hitchon⁷, Boulos Haraoui⁸, Edward C. Keystone⁹, Diane Tin¹⁰, J Carter Thorne¹¹, Janet E. Pope¹², VP Bykerk⁴ and CATCH Investigators and OMERACT Flare Group, ¹Clinical Epidemiology, McGill University, Montreal, QC, Canada, ²Division of Rheumatology, Johns Hopkins School of Medicine, Baltimore, MD, ³Rheumatology, Johns Hopkins University, Baltimore, MD, ⁴Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁵Hospital for Special Surgery, New York, NY, ⁶Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁷Department of Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ⁸Institut de Rhumatologie, Montreal, QC, Canada, ⁹Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹⁰The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹¹University of Toronto, Toronto, ON, Canada, ¹²University of Western Ontario, London, ON, Canada
Background/Purpose: Early rheumatoid arthritis (ERA) patients attending office visits often report being in a disease flares. We evaluated patient reports of flare in relation to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].